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The role of platelets in the process of restenosis after percu-
taneous coronary intervention is not fully understood. After
vascular injury there is extensive platelet activation, adhesion,
aggregation and secretion. Through the liberation of growth
factors, such as platelet-derived growth factor, and surface ex-
pression of cell adhesion molecules, such as the glycoprotein
IIb/IIIa integrin, platelets appear to be a pivotal mediator of the
vascular injury response. Experimental models have demon-
strated that profound, prolonged thrombocytopenia, or blockade
of the IIb/IIIa receptor, may reduce neointimal hyperplasia after
arterial balloon injury. However, multiple clinical trials testing
conventional or new platelet agents have not yielded any salutary
effects. The recent ﬁnding that abciximab, a monoclonal antibody
fragment directed against IIb/IIIa, reduced clinical restenosis
after coronary angioplasty by 26% in patients raises questions
about the mechanism of beneﬁt. The v3 vitronectin receptor is
responsible for binding endothelial cells to platelets, and it also
has a key role in modulating smooth muscle cell migration. It is
possible that the antibody fragment exerts its effect on restenosis
by means of v3, because abciximab fully cross-reacts to this
integrin owing to the shared 3 subunit. To date, the other platelet
glycoprotein IIb/IIIa inhibitors, including Integrelin, Tiroﬁban,
Lamiﬁban and Xemiloﬁban, are speciﬁc in binding to this partic-
ular integrin. Considerable further study is necessary to unravel
the effects of platelets on the restenosis process.
(J Am Coll Cardiol 1996;28:1643–51)
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Restenosis after percutaneous coronary intervention, initially
recognized nearly 20 years ago (1), remains the main limitation
of the technique (2–6). A large number of clinical trials testing
pharmacologic approaches have failed to reduce the incidence
of 30% to 40% of patients with signiﬁcant angiographic
recurrence. There has been unexpected difﬁculty in deriving
clinical therapeutic interventions from agents demonstrated to
be effective in experimental models. Recently, the ﬁrst signif-
icant pharmacologic-mediated reduction in clinical restenosis
in the human was reported (7). The drug was a monoclonal
antibody fragment, and its target was the platelet glycoprotein
IIb/IIIa receptor. The purpose of this review is to discuss the
role of platelets in intimal hyperplasia and the potential of
these cells as a therapeutic target to reduce restenosis.
Role of Platelets in Intimal Hyperplasia
Balloon angioplasty disrupts the continuity of the endothe-
lium and induces deep arterial injury, exposing the subendo-
thelium to the blood. The injury sets up key adhesive interac-
tions between cells and their ligands. The circulating “resting”
platelets can recognize adhesive substrates and rapidly adhere
to the damaged surface. The adhesive response of platelets
represents an initial step, which may be followed by platelet
secretion and aggregation (8). Platelet secretion results in the
local release of intracellular granule constituents, including
diphosphate, serotonin, thromboxane A2, ﬁbrinogen, ﬁbronec-
tin and von Willebrand factor (vWF). These substances con-
tribute to the activation of neighboring platelets and induce
aggregation and thrombus formation. Other released sub-
stances include chemokines and mitogens such as platelet-
derived growth factor (PDGF), transforming growth factor-
beta (TGF-beta) and basic ﬁbroblast growth factor (b-FGF).
These growth factors stimulate the migration and proliferation
of smooth muscle cells (8,9), which are considered to be pivotal
to the formation of a neointimal lesion. When a PDGF
neutralizing antibody was administered to rats subjected to
balloon carotid injury (10), the development of an intimal
lesion was inhibited by 40%, predominantly by inhibition of
smooth muscle cell migration. Infusion of b-FGF for 8 h in the
same animal model was followed by increased smooth muscle
cell replication 24 to 48 h later (11), and an antibody to b-FGF
suppressed this response (12). Recently, an in vitro experiment
conﬁrmed that platelets, or growth factors (PDGF, b-FGF,
epidermal growth factor, interleukin-1) alone or in combina-
tion, stimulated proliferation of human coronary smooth mus-
cle cells derived from atherectomized restenotic lesions (13).
Furthermore, in vivo data from the porcine injury model also
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emphasize the importance of PDGF for the effect of
interleukin-1-beta on promoting intimal hyperplasia (14).
Platelet deposition occurs immediately after the arterial
injury, but the time during which active platelet accumulation
continues is species dependent (15–17). The degree of platelet
deposition and thrombosis is determined mainly by the degree
of arterial wall injury (18,19), but also by the transport of
platelets to the injured area (20). Platelet transport is largely
determined by the wall shear rate. Abnormally high shear
stress, such as that which occurs in stenosed arteries, can
activate and aggregate platelets in the absence of exogenous
agonists (21–24). Thus, in the context of coronary angioplasty,
if a signiﬁcant residual stenosis remains, platelet deposition
may be increased because of elevated shear stress at the site of
the lesion (25,26).
Experimental Studies Implicating Platelets
in Restenosis
In 1977, the important role of platelets in restenosis was
highlighted by Friedman et al. (27) in a thrombocytopenic
animal study. Thrombocytopenia was induced in rabbits and
maintained until their death by daily injections of antiplatelet
serum to maintain a daily platelet count 7,000/cm3. The
abdominal aorta and right iliac arteries were denuded of
endothelium by a balloon catheter. The prolonged, severe
thrombocytopenia was found to inhibit neointimal formation
after balloon injury. Rabbits given the antibody 2 to 3 days
before the injury failed to develop intimal thickening. As an
extension of this ﬁnding, the inhibition of intimal hyper-
plasia was related to the degree of thrombocytopenia.
Sustained thrombocytopenic levels 7,000/cm3 were neces-
sary to inhibit neointimal formation. Of note, the extent of
re-endothelialization, as assessed by Evans blue stain, was not
affected by the extent of thrombocytopenia. Fingerle et al. (17)
subsequently conﬁrmed in a rat model that the absence of
platelets at the site of injury inhibited formation of intimal
lesions, although neither the time of onset nor the extent of
smooth muscle cell replication was affected. The main mech-
anism appeared to be through inhibition of smooth muscle cell
migration. In this study, thrombocytopenia was also induced by
an antiplatelet antibody and was severe at the time of the
injury (1% of normal platelet count). By 48 h, platelet counts
had signiﬁcantly increased and were normal by 96 h. The size
of intimal lesions at 4 and 7 days were signiﬁcantly reduced as
compared with control rats, but by 14 days the intimal areas
were the same for both groups. When the animals were kept
thrombocytopenic for an observation period of 7 days, no
intimal lesions were present.
Induction of thrombocytopenia is an impractical clinical
approach to prevent restenosis. Thus, agents that block platelet
activation have been tested. It has been shown in animal
studies that platelet deposition at the site of balloon injury can
be signiﬁcantly reduced by pretreatment with antiplatelet
agents. In the pig model, there is a signiﬁcant reduction with
pretreatment with aspirin alone or aspirin combined with
dipyridamole (19). In a rabbit model, the intravenous admin-
istration of aspirin or a thromboxane synthetase inhibitor was
similarly effective in reducing platelet deposition after angio-
plasty (28).
Only a few animal studies have tested the effect of gener-
alized antiplatelet therapy on restenosis. Two studies (29,30),
using the same rabbit model of atherosclerosis, examined the
effect of a combination of aspirin and dipyridamole adminis-
tered orally. The treatment was introduced 1 or 2 days before
angioplasty and maintained until the time of death. In one
study, antiplatelet drugs signiﬁcantly reduced the incidence of
restenosis (29), whereas in the second study (30) this regimen
was ineffective despite an almost total inhibition of platelet
aggregation to collagen.
Early Clinical Trials
Early clinical trials failed to demonstrate any beneﬁcial
effect of antiplatelet agents on restenosis after coronary angio-
plasty, although the acute complications were signiﬁcantly
reduced. Schwartz et al. (31) evaluated the role of high dose
aspirin (330 mg three times daily, introduced 24 h before
coronary angioplasty) with dipyridamole in reducing the rate
of restenosis in patients after successful angioplasty. The use of
this antiplatelet regimen did not reduce the 6-month rate of
restenosis, but it markedly reduced the incidence of peripro-
cedural myocardial infarction (1.6% in the treated group vs.
6.9% in the placebo group) (31). These data were conﬁrmed
by another study using the same combination, aspirin
(975 mg/day) with dipyridamole (225 mg/day) (32). Ticlopi-
dine, another platelet inhibitor, was also ineffective in reducing
restenosis at a dose of 250 mg twice daily, compared with
aspirin/dipyridamole and placebo (33,34). Serruys et al. (35)
tested a potent and speciﬁc thromboxane A2 receptor blocking
drug in a randomized, placebo-controlled trial. At follow-up,
the loss of minimal lumen diameter was identical in the control
and treated groups, despite a 90% reduction of platelet
aggregation through the thromboxane A2 pathway in the
treated group. Another trial conﬁrmed that either selective
thromboxane A2 receptor antagonism with Sulotroban or
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nonselective thromboxane A2 receptor antagonism with aspirin
had no effect on the rate of angiographically detected resten-
osis at 6 months after coronary angioplasty (36,37).
There are several potential explanations for why these
clinical trials have failed to demonstrate the ability of anti-
platelet agents to prevent restenosis after coronary angio-
plasty. First, there are no data to substantiate a reduction of
platelet accumulation at the site of injury (16). Numerous
platelet agonists, including thrombin, collagen, adenosine
diphosphate and high shear, can stimulate platelets even in the
face of aspirin therapy (38). Second, even a major reduction in
the aggregation response of platelets may be insufﬁcient to
prevent a substantial release of the chemokines involved in the
initiation of the proliferative response. Factors released from
other cell types (injured endothelial cells, injured medial
smooth muscle cells or white blood cells) may play an impor-
tant role. Third, these antiplatelet agents have negligible
effects on platelet adhesion.
Thus, the failure of the antiplatelet agents tested in clinical
trials should not lead to the conclusion that platelets are not
involved in restenosis or are an inappropriate therapeutic
target. In the last decade, platelet membrane receptors in-
volved in fundamental aspects of platelet adhesion and aggre-
gation have been identiﬁed and have been candidate targets
for more effective antiplatelet therapy. These new agents are
already under investigation in experimental studies and in
clinical trials. First we brieﬂy describe the platelet receptors,
and then we update the status of in vivo studies, testing the
blocking of these receptors to limit the vascular injury re-
sponse.
Platelet Membrane Receptors
The platelet membrane receptors have been the subject of
recent reviews (39–43). It was the detection of speciﬁc abnor-
malities in platelets isolated from patients with inherited
disorders of platelet aggregation (Glanzman’s thrombasthe-
nia) and adhesion (Bernard-Soulier syndrome) that provided
the ﬁrst real clue that membrane glycoproteins were essential
to platelet functions (44). These functions include platelet
attachment to a diverse number of extracellular matrix pro-
teins, including vWF, collagen, ﬁbronectin and laminin. In
particular, the promiscuous ability of glycoprotein (GP) IIb-
IIIa complexes to bind ﬁbrinogen and other adhesive proteins
is a key to hemostasis. Table 1 summarizes some of the
essential functions of the platelet membrane glycoproteins.
Several of them are involved in adhesion with a main role for
the GP Ib-IX complexes.
Adhesion receptors. Platelet adhesion is a multistep pro-
cess in which attachment is followed by activation and spread-
ing on the exposed surface. The platelets adhere only when the
endothelial surface is interrupted, exposing the subendothelial
substrates such as collagen, vWF, ﬁbronectin, vitronectin and
laminin. The major receptors involved have been identiﬁed.
GP Ib is present in the platelet membrane in a tight
complex with a low molecular weight component, GP IX
(45,46). About 25,000 copies are found on unstimulated plate-
lets (45). GP Ib-IX complexes mediate the adhesion of un-
stimulated platelets to vWF bound within the subendothelium
of damaged vessels. In particular, they anchor the platelets to
the subendothelium under high shear conditions. Attachment
of platelets to vWF leads to activation, granule secretion and
platelet aggregation (23,47). Moreover, GP Ib has at least one
binding site to alpha thrombin and there is some evidence
linking GP Ib to platelet activation by thrombin (48).
Although platelet attachment to subendothelium depends
primarily on the GP Ib–vWF interaction, other platelet recep-
tors are also involved, including the integrins. The integrins
constitute a widespread family of receptors that mediate many
cell–cell and cell–substratum interactions (48–50). All inte-
grins are heterodimers of alpha and beta subunits. Platelets
contain ﬁve integrins, two of the 3 subfamily (IIb3, v3)
and three of the 1 subfamily (21, 51, 61) (51). The 21
receptor (GP Ia-IIa complex) is a universal receptor for type I
collagen that is the most thrombogenic macromolecular con-
stituent in the subendothelium and that not only serves as an
effective substrate for platelet adhesion, but is also a potent
initiator of platelet aggregation. The 51 (GP Ic-IIa complex)
plays a role in platelet adhesion to ﬁbronectin and the 61
(GP Ic-IIa complex) in platelet adhesion to laminin. The exact
role of the various 1 integrins in platelet adhesion in vivo
remains to be evaluated.
Aggregation receptors. Activation of the GP IIb-IIIa re-
ceptor is the ﬁnal common pathway involved in platelet
aggregation (42). Binding studies with monoclonal antibodies
reveal 50,000 to 75,000 copies of GP IIb-IIIa on each rest
platelet. When platelets are stimulated with physiologic ago-
nists, GP IIb-IIIa undergoes a conformational change that
enables it to bind ﬁbrinogen. It was established that other
adhesive proteins are also able to bind to activated GP IIb-IIIa.
These include vWF, ﬁbronectin and vitronectin. These inter-
actions are mediated by Arg-Gly-Asp sequences (RGD) within
these ligands. Although ﬁbrinogen can bind to GP IIb-IIIa by
its RGD sequences, an amino acid sequence located at the
carboxy-terminus of the gamma chain is primarily involved in
its binding to GP IIb-IIIa (52). RGD containing peptides and
gamma chain peptides are inhibitors of the binding of ﬁbrin-
ogen to activated GP IIb-IIIa (53,54).
Table 1. Major Glycoprotein Receptors Involved in Platelet
Adhesion and Aggregation
Receptors Ligand Function
Leucin-rich protein:
Ib-IX
vWF, thrombin Adhesion
Integrins
Ia-IIa (21) Collagen Adhesion
Ic-IIa (51) Fibronectin Adhesion
Ic-IIa (61) Laminin Adhesion
IIb-IIIa (2b3) Fibrinogen, vWF, ﬁbronectin,
vitronectin
Aggregation
VnR (v3) Vitronectin, ﬁbrinogen, vWF ?
VnR  vitronectin receptor; vWF  von Willebrand factor.
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Fibrinogen binding to activated GP IIb-IIIa complexes is
thought to mediate aggregation by binding platelets together
(Fig. 1) (55). As in platelet adhesion, shear rate also plays a
role in platelet aggregation. At high shear rates, the aggrega-
tion may be more dependent on vWF than on ﬁbrinogen (22).
With distinct and different binding sites for GP Ib and IIb-IIIa,
vWF may actively participate in both platelet adhesion and
aggregation.
The v3 Integrin
Platelets express two 3 receptors, not only IIb3 (GP
IIb-IIIa), but also v3 (vitronectin receptor). Although v3 is
present in platelets, it is a minor component. Studies with v3
speciﬁc monoclonal antibodies suggest that as few as 50
molecules are expressed on the platelet surface (56,57). The v
and IIb subunits have 36% sequence identity (58). In humans,
GP IIb-IIIa complexes are conﬁned to platelets and cells of the
megakaryocyte lineage, whereas v3 is heavily expressed by
numerous cells, including endothelial cells, monocytes, smooth
muscle cells and melanoma cells (59–63). Although the func-
tional role of platelet v3 has not been established, the v3
integrin is thought to play a major role in the adhesion and
migration of smooth muscle cells and endothelial cells on
extracellular matrix, and consequently in the restenotic pro-
cess. This integrin appears to bind several extracellular matrix
proteins (vitronectin, ﬁbronectin, thrombospondin, laminin,
collagen I and IV), and antiserum against this receptor inhibits
smooth muscle cell migration on all substrates (64). Moreover,
v3 binds osteopontin, another matrix protein, whose role was
recently described (65–67). Osteopontin promotes adhesion
and migration of both vascular smooth muscle cells and
endothelial cells through an RGD-mediated interaction (65–
67). An antibody against v3 partially inhibits smooth muscle
cell and endothelial cell adhesion and migration to osteopon-
tin. Vitronectin-induced human aortic smooth muscle cell
migration is also mediated, at least in part, by the v3
receptor (60). Moreover, v3 appears to mediate endothelial
cell spreading and migration (68) and might promote the
survival of endothelial cells after the arterial injury and the
regrowth of the monolayer (67). In addition, it might be
possible for both a platelet and an endothelial cell to bind the
same ﬁbrinogen molecule through their 3 integrins—IIb3
and v3, respectively (Fig. 1) (69). This additional mechanism
for platelet adhesion may play a role in the restenosis process.
Glycoprotein IIb-IIIa Antagonists
A series of compounds—antibodies, peptides and small
molecules—has been developed to antagonize GP IIb-IIIa
function. These compounds have been shown to be much more
effective than aspirin in animal models of thrombosis and have
considerable promise in cardiovascular medicine, as discussed
in recent reviews (70,71). Several of these compounds have
undergone preliminary evaluations in humans and are under
investigation in large clinical trials.
Monoclonal antibody. The ﬁrst platelet ﬁbrinogen receptor
blocker tested in patients was a murine monoclonal antibody
known as 7E3 (Centocor) developed by Coller (72). The
antibody preparation has been substantially modiﬁed over
time. As originally developed, the monoclonal antibody 7E3
was entirely murine in composition. Because of concern about
immunogenicity, a chimeric monoclonal 7E3 Fab (c7E3 Fab)
was created by means of genetic reconstruction. This new
Figure 1. Schematic representation of the main receptors
involved in platelet adhesion and aggregation. Several of the
different molecules involved in the various cell–cell interac-
tions discussed can have multiple ligands (e.g. vWF has
distinct sites for both GP Ib and GP IIb/IIIa).
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molecule consists of the variable region derived from the
original murine protein (imparting speciﬁcity to the integrin
GP IIb-IIIa) hybridized with the remaining human constant
region of the Fab fragment of an immunoglobulin G molecule.
Chimeric 7E3 (abciximab) appears to be considerably more
effective than current antiplatelet agents in preventing platelet
aggregation. Turner et al. (73) recently reported that under
ﬂow conditions of abnormally increased shear stress analogous
to those in narrowed coronary arteries (in vitro study), the in
vivo injection of c7E3 Fab, in contrast to heparin or aspirin,
markedly reduced platelet aggregate formation mediated by
the binding of ﬁbrinogen and vWF to platelet GP IIb-IIIa.
The pharmacodynamic properties of c7E3 Fab were eluci-
dated during phase II clinical investigations and have been
previously described (74). Chimeric 7E3 Fab produces a
dose-dependent blockade of platelet GP IIb-IIIa receptors,
which is correlated with inhibition of the platelet aggregatory
response. Platelet function, evaluated by measurements of
platelet aggregation, GP IIb-IIIa blockade and bleeding time
began to recover within 6 h of the cessation of infusion. These
variables do not completely return to normal for at least 2 to 4
days. Reversion of normal platelet aggregation is dependent
on new platelets released into the circulation. Another recent
study investigated the effects on ex vivo shear-induced platelet
aggregation of c7E3 Fab administered to patients undergoing
coronary angioplasty (75). The results conﬁrm that c7E3 Fab
injection results in a rapid, extensive blockade of GP IIb-IIIa
receptors (98%) and a 50% inhibition of ex vivo platelet
aggregation induced by shear stress. Partial reversibility of the
inhibition was noted within 2 days after drug administration
(still 30% inhibition), but even after 1 week, platelet function
had not been fully restored. Thus, a potential limitation of the
antibody is an increased bleeding risk. In contrast, the pro-
tracted effect on platelet function may highlight a distinct
advantage.
Peptides and peptidomimetics. The peptidomimetics and
peptides have two theoretical advantages over 7E3. First, there
is a reduced risk of immunogenicity, although the clinical
importance of this phenomenon in the case of c7E3 Fab
remains to be established. Second, many of these compounds
have a shorter duration of action, implying that adverse effects
might be more manageable by cessation of the infusion.
Moreover, another advantage is the oral bioavailability of
some of those molecules. Several synthetic peptides have been
developed (76–81), including cyclic RGD peptides and In-
tegrelin (COR Therapeutics), a cyclic KGD (Lys-Gly-Asp)
heptapeptide actively under investigation in clinical trials. This
latter peptide may be an even more speciﬁc inhibitor of GP
IIb-IIIa than RGD-containing peptides. Moreover, RGD de-
rivatives (modiﬁcation of the RGD sequence to improve
stability and activity) and peptidomimetics have been designed
(82–98). Two peptidomimetics, Tiroﬁban (MK-383) and Lami-
ﬁban (Ro-44 9883), have already been studied in phase II
clinical trials and are currently being assessed in phase III trials
of unstable angina.
Experience With Glycoprotein Antagonists
in Restenosis
Glycoprotein IIb-IIIa antagonists. Experimental studies.
The effect of GP IIb-IIIa antagonists in preventing the re-
sponse to vascular injury has been examined in several animal
studies. Azrin et al. (99) tested in a rabbit model of balloon
angioplasty an antibody (AZ-1) that binds to the rabbit platelet
GP IIb-IIIa receptor and inhibits platelet function both in vitro
and in vivo. The rabbits were randomized to receive a single
bolus of placebo 20 min before angioplasty, a single bolus of
AZ-1 or two boluses of AZ-1 given 3 days apart. After a single
bolus, platelet aggregation remained abnormal (initially80%
inhibition) for 72 h. Two intermittent boluses achieved platelet
inhibition for longer than 6 days. With respect to intimal area
or minimal lumen diameter, however, there were no signiﬁcant
differences between the AZ-1 antibody-treated and control
groups 4 weeks after angioplasty. With the intermittent dosing,
it is possible that the GP IIb-IIIa blockade was not sustained
long enough to prevent the intimal hyperplasia. Alternatively,
injection of foreign intact antibody may have induced an
immunologic response, as suggested by the investigators (99),
that had counterbalancing effects on the response to vascular
injury in this rabbit model of atherosclerosis.
In contrast to this negative study, Matsuno et al. (80), using
a hamster carotid artery model of restenosis, demonstrated
that a nonspeciﬁc RGD peptide (G4120, Genentech, Inc.), an
inhibitor of both integrins IIb3 and v3, inhibited neointima
hyperplasia in a dose-dependent fashion, when administered
for the complete observation period. A shorter treatment
period (7 days) was not effective, indicating that integrin
inhibition is needed beyond the ﬁrst few days. This late
beneﬁcial effect may be related to the inhibition of smooth
muscle cell v3 receptors.
Clinical trials. In the Evaluation of IIb/IIIa Platelet Recep-
tor Antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial (100) the chimeric 7E3 monoclonal antibody
(abciximab) was tested in 2,099 patients undergoing high risk
coronary interventions with unstable angina, recent or evolving
myocardial infarction or high risk angiographic morphology.
Patients were clinically followed up for at least 6 months to
determine the need for repeat revascularization and the oc-
currence of ischemic events (7). At 6 months, there was a 23%
reduction in the rate of major ischemic events or elective
repeat coronary revascularization in the treated group com-
pared with the placebo group when abciximab was adminis-
tered as a bolus followed by a 12-h intravenous infusion (Fig.
2). The bolus-only group had an intermediate outcome that
was not signiﬁcantly better than that of the placebo group.
The EPIC study was the ﬁrst clinical trial to demonstrate
that platelet aggregation inhibition sustained for at least 36 to
48 h after the procedure was associated with a reduced rate of
clinical restenosis. However, there are some limitations that
do not permit deﬁnitive conclusions. First, no systematic
angiographic follow-up at 6 months was performed to conﬁrm
the mechanistic effect. Another large-scale trial of abciximab
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for restenosis, which includes systematic angiographic follow-
up, is currently ongoing (Evaluation of PTCA to Improve
Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade
[EPILOG]). Second, because v3 is very closely related to
IIb3 by virtue of its common beta subunit, abciximab fully
cross reacts with v3, as do certain peptides and peptidomi-
metics (101). Thus, the beneﬁcial effect of c7E3 could be
related to the blockade of v3 rather than GP IIb/IIIa, or the
blockade of both receptors may be necessary.
The beneﬁt of selectively blocking GP IIb/IIIa was assessed
in another large clinical trial (Integrelin to Minimize Platelet
Aggregation and Coronary Thrombosis [IMPACT II]) involv-
ing 4,010 patients with Integrelin, which has marked speciﬁcity
for GP IIb/IIIa. This trial included three treatment groups, a
placebo group and two Integrelin groups. Each of the two
Integrelin groups received 135 mg/kg body weight bolus fol-
lowed by a 20-h infusion of 0.5 mg/kg (“low dose”) or
0.75 mg/kg (“high dose”). Patients were followed clinically at
30 days and angiographically at 6 months in a subset of 918
patients. At 30 days, there was a trend toward a reduction in
end points (death, myocardial infarction, repeat urgent or
emergency percutaneous coronary intervention or coronary
artery bypass surgery) in the treated groups (11.4% in placebo,
9.2% Integrelin low dose, 9.9% Integrelin high dose), but the
results were not statistically signiﬁcant. In the angiographic
substudy, the rates of restenosis at 6 months, deﬁned by 50%
diameter restenosis, were not signiﬁcantly different in the three
groups. Thus, according to these results, a 20-h blockade of the
GP IIb-IIIa receptor with a speciﬁc antagonist does not
prevent restenosis after coronary angioplasty. Possible expla-
nations include a lack of adequate duration of the GP IIb-IIIa
effect, inadequate dosing for maximal inhibition of platelet
aggregation or speciﬁcity of the GP IIb-IIIa effect. It may be
necessary, in light of our current knowledge of the integrin
v3, to also achieve its blockade and avoid speciﬁcity to GP
IIb-IIIa.
v3 antagonists. The potential therapeutic beneﬁt of
v3 blockade has been reported by Choi et al. (102). In an in
vitro assay, a monoclonal antibody to human v3 inhibited the
migration of human aortic smooth muscle cells. However, this
inhibition was not complete, and other integrins probably play
a role in smooth muscle cell motility. A cyclic RGD peptide
antagonist of v3 (GpenGRGDSPCA, Telios Pharmaceuti-
cals) has a similar inhibitory effect on human and rabbit
smooth muscle cell migration. The same investigators also
tested the effects of the local administration of this RGD
peptide in a rabbit model of balloon carotid artery injury. The
agent, delivered locally through a microcatheter connected to
an osmotic pump until the time of sacriﬁce (2 weeks), pre-
vented neointimal formation by 70%. The same peptide locally
applied to the carotid artery through an adventitial pluronic gel
in rats led to a 92% reduction in hyperplasia after injury (103).
These results were conﬁrmed by those of Lundgren et al. (104),
who also applied an v3 antagonist (a cyclic RGD peptide) by
use of a gel, after carotid balloon injury in the rabbit model. At
28 days, there was a signiﬁcant decrease (76%) in the mean
intima/media ratio in the treated group compared with the
control group.
Glycoprotein Ib antagonists. Like the v3 antagonists, the
GP Ib antagonists have only been tested in experimental
studies. VCL, an antagonist of the von Willebrand–GP Ib
binding domain, inhibits botrocetin and ristocetin GP Ib–
dependent platelet agglutination (105), inhibits platelet adhe-
sion at the site of arterial injury and reduces platelet deposition
in a rat model of arterial thrombosis (106). In a recent study,
Zahger et al. (107), using a rat model of femoral artery injury,
conﬁrmed that VCL profoundly decreased platelet deposition
at the site of balloon injury. This effect was associated with a
signiﬁcant reduction of the intimal thickening. The agent was
Figure 2. Event-free survival of patients at 30 days and 6 months in
the EPIC trial (7,100). (Right panel adapted from Topol et al. [7], with
permission.)
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administered as an intravenous bolus 15 min before the injury,
followed by continuous intravenous administration by an infu-
sion pump for 3 days. Platelet adhesion reductions of 83% and
88% were observed at 1 day and 3 days, respectively. At 14
days, there was a 60% reduction in the intima media ratio.
Because no effect was observed on smooth muscle cell prolif-
eration, the mechanism was presumed to be an inhibition of
cell migration or matrix deposition.
Conclusions
Platelets play an important role in the restenosis process
after balloon angioplasty. Early experimental studies high-
lighted this role. Thrombocytopenia inhibits the intimal hyper-
plasia after arterial injury, provided it is established well before
the time of injury and is sustained. Previous experimental
studies and clinical trials testing antiplatelet drugs have been
disappointing, suggesting that new and more powerful agents,
such as the GP IIb/IIIa antagonists, may be required. These
agents represent new hope to reduce restenosis after coronary
angioplasty, as suggested by 6 months of follow-up in the EPIC
study. Nevertheless, important questions remain to be an-
swered. Blockade of only the GP IIb/IIIa receptor for a limited
period (36 h) may be not sufﬁcient, as suggested by the
results of the IMPACT II angiographic substudy. Further
investigation will be necessary to determine whether other
receptors, especially v3 alone or in combination with GP
IIb/IIIa antagonists, are critical in preventing restenosis.
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